FIELD: chemical-pharmaceutical industry.
SUBSTANCE: invention relates to taxane compounds having a structure represented by the following general formula I:
where R1 is benzoyl, tert-butyloxycarbonyl or N,N'-dimethylcarbamoyl; R2 is phenyl, 
or 
R3 is -OMe, -OOCOC3, -OCON (CH3)2 or -OCOSC2H5; R4 is -OMe, -OOCOC3, -OCON (CH3)2, -OCOSC2H5, H or OH, or their pharmaceutically acceptable non-toxic salts or isomers. Invention also discloses an anti-tumor pharmaceutical composition, use of taxane compounds and a pharmaceutical composition, a method of producing taxane compounds.
EFFECT: disclosed compounds have improved oral bioavailability and are characterized by strong cytotoxicity with respect to a number of human cancer cell lines and broad spectrum anti-tumor effects.
1 cl, 62 dwg, 21 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TAXANE COMPOUNDS AND ALSO THE PRODUCTION METHOD AND USE THEREOF | 2014 |
|
RU2686675C1 |
| DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
| C-4 CARBONATE-COMPRISING TAXANES | 2000 |
|
RU2243223C2 |
| SEMI-SYNTHETIC TAXANES AND PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF | 2001 |
|
RU2259363C2 |
| SYNTHESIS OF HALICHONDRINS | 2018 |
|
RU2794176C2 |
| C-2'-METHYLATED DERIVATIVES OF PACLITAXEL FOR USING AS ANTITUMOR AGENTS | 2002 |
|
RU2287528C2 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
| DERIVATIVES OF TAXANE, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 2000 |
|
RU2245882C2 |
| METHOD OF PRODUCING LOSARTAN | 2006 |
|
RU2412940C2 |
